BiotechTube
Nordic Bioscience

Nordic Bioscience

Herlev, Denmark· Est.
nordicbioscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $13.5M

Overview

Nordic Bioscience is a mature, privately held biotech firm with over 30 years of expertise in extracellular matrix research. Its core asset is the Nordic ProteinFingerPrint Technology™, a biomarker platform that measures tissue remodeling activity to support precision drug development across numerous therapeutic areas. The company generates revenue through biomarker sales (including 'Kit in a Box' products) and a high-volume laboratory services business, having delivered over 500,000 test results in 2024. It positions itself as a critical enabler for pharmaceutical R&D, offering insights unmatched by traditional omics approaches.

CardiologyDermatologyGastroenterologyHepatologyNephrologyNeurologyObesity and metabolic disordersOncologyRheumatologyPulmonology

Technology Platform

Nordic ProteinFingerPrint Technology™: A proprietary platform that uses immunoassays to quantify specific, enzymatically cleaved fragments of extracellular matrix (ECM) proteins in blood. These neo-epitope biomarkers provide mechanistic insights into tissue remodeling and disease activity.

Funding History

2
Total raised:$13.5M
Series A$12M
Grant$1.5M

Opportunities

The global shift towards precision medicine and biomarker-driven drug development creates strong demand for its mechanistic biomarkers.
Expansion of its 'Kit in a Box' products allows it to scale beyond service-based revenue and embed its technology in client labs.
Regulatory qualification of its biomarkers as drug development tools could provide a significant competitive moat and drive higher-value partnerships.

Risk Factors

Scientific acceptance of ECM biomarkers is not universal, and competition from broader omics platforms is intense.
Revenue is likely dependent on a concentrated customer base of large pharmaceutical companies, creating client concentration risk.
Scaling laboratory operations while maintaining quality for high test volumes presents an ongoing operational challenge.

Competitive Landscape

Nordic Bioscience competes with large central laboratory service providers (e.g., LabCorp, Q2 Solutions), broad proteomics platform companies (e.g., Olink, SomaLogic), and other specialty biomarker firms. Its key differentiation is deep specialization in ECM biology and mechanism-based biomarkers, rather than broad discovery. It positions itself as offering greater precision and pharmacological insight than associative omics approaches.

More companies in Diagnostics & Precision Medicine →More companies in Denmark →